美国安进地诺单抗价格多少？

On June 2, 2010, it was approved by the United States (FDA) for use in postmenopausal women with the risk of osteoporosis. In November 2010, the brand name Xgeva was approved for the prevention of bone-related events in patients and the treatment of solid tumors with bone metastasis. Denosumab is the first RANKL inhibitor approved by the FDA. On June 13, 2013, the U.S. Food and Drug Administration approved denosumab for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or in which resection would result in significant morbidity.

On October 26, 2018, Amgen Pharmaceuticals submitted a marketing application in China, with the application name: denosumab. On May 23, 2019, the China National Medical Products Administration announced conditional approval of the import registration application for denosumab. The drug will be used to treat adults and skeletally mature adolescent patients with unresectable giant cell tumors of bone or whose surgical resection may result in severe functional impairment.

How much does Amgen denosumab cost in the United States?

Amgen's denosumab in the United States is an original drug and is exported to different countries at different prices. The following is the price of denosumab in the United States, China, and Turkey compiled by Medical Companion Travel.

Denosumab produced by Amgen/Amgen Biopharmaceuticals of the United States is exported to China. Specification: 120mg/1.7ml bottle/box. Pharmacy price: RMB 5,298.00.

The selling price of denosumab produced by Amgen/Amgen Biopharmaceuticals in the United States, specification: 60mg/1ml tube/box, price: US$1,169.98.

The product produced by Amgen/American Amgen Biopharmaceuticals and exported to Turkey is 120 mg and sells for about $1,500.

Recommended related hot articles: /newsDetail/85799.html